This book provides a research-based overview of the use of psychotropic medications in combination with psychosocial interventions to improve learning, social interactions, and behavioral functioning of children within the school setting. It details implementation strategies for delivering multimodal treatments to school-aged children with psychiatric diagnoses while coordinating services across educational and health service sectors. In addition, it includes case studies on ADHD, conduct disorder, depression, social anxiety, autism spectrum disorder, bipolar disorder, and psychosis, with overviews of treatment plans, targeted goals and behaviors, classroom-based medication evaluation plans, and treatment responses communicated back to the child’s family and physician. The book concludes with an overview of integrated behavioral health and the benefits of care coordination to school-aged children experiencing social, emotional, and behavioral challenges. Topics featured in this text include: Legal, ethical, and professional issues related to the use of psychotropic medications in school-aged populations. Effective medications for treating mood dysregulation disorders in school-aged youth. Medications for internalizing and externalizing disorders. Common side effects of psychotropic medication in school-aged populations. The need to be culturally sensitive when considering treatment plans for school-aged youth. School Psychopharmacology is an essential resource for researchers, graduate students, and other professionals in child and school psychology, social work, psychiatry, psychopharmacology, special and general education, public health, and counseling.
When the first edition of Pediatric Psychopharmacology published in 2002, it filled a void in child and adolescent psychiatry and quickly establishing itself as the definitive text-reference in pediatric psychopharmacology. While numerous short, clinically focused paperbacks have been published since then, no competitors with the scholarly breadth, depth, and luster of this volume have emerged. In the second edition, Christopher Kratochvil, MD, a highly respected expert in pediatric psychopharmacology, joins the outstanding editorial team led by Dr. Martin and Dr. Scahill. In the new edition, the editors streamline the flow of information to reflect the growth in scientific data since the first edition appeared. The overall structure of the book remains the same, with major sections on underlying biology; somatic interventions; assessment and treatment; and special considerations.
The last twenty-five years have witnessed an explosion of knowledge about the influence of brain biochemistry on mood and behavior and about pharmacological approaches to treating mental and emotional disorders. A substantial portion of patients seen in clinical practice are taking some medication or might usefully be advised to do so. But many clinical psychologists, social workers, and counselors need additional information in order to better treat patients already on medication, know when and to whom to refer new patients for psychiatric consultation, and work collaboratively with psychiatrists when appropriate. Michael J. Gitlin's indispensable first edition of The Psychotherapists Guide to Psychopharmacology has now been updated and revised -- this new second edition now reflects major changes that have influenced the clinical arena in the last five years such as the recent release of DSM-IV and the domination of the psychopharmacological field by the selective serotonin reuptake inhibitors, such as fluoxetine (Prozac). The Psychotherapists Guide to Psychopharmacology, Second Edition also now includes coverage of attention deficit/hyperactivity disorder and contains updated sections on the new antipsychotics for schizophrenia and the increased use of anticonvulsant mood stabilizers for bipolar disorder. The book also includes other significant changes that have influenced the field over the last few years, such as brain imaging studies, research in obsessive compulsive disorder and social phobia, and such prominent topics in women's health as pregnancy, PMS, postpartum disorders, and breast feeding. This revision of an already established guide will again be an essential reference for all nonmedical professionals involved in treating mental and emotional disorders.
The third edition reflects advances in this rapidly growing field and includes the latest research on the psychopharmacological treatment of children. Each chapter has been revised and updated in detail, emphasizing what has been learned since the last edition.
The new, third edition of the Clinical Manual of Child and Adolescent Psychopharmacology has been thoroughly revised, yet its mission remains the same: to keep clinicians up-to-date on the latest research so that they can provide state-of-the-art care to their young patients. To this end, the book describes and explores those elements that are specific to pediatric psychopharmacology; this defines and positions the volume at the nexus of child and adolescent psychiatry, pediatrics, and pharmacology. A stellar roster of contributors addresses new treatments for youths with disruptive behavior disorders, mood disorders, anxiety disorders, pervasive developmental disorders, and psychotic illnesses and tackles some of the most important emerging issues in the field. For example, advances in understanding the long-term treatment effects of medications in pediatric populations are thoroughly reviewed, including not only maintenance studies that consider the durability of efficacy but also clinical trials of greater duration designed to specifically evaluate long-term safety. In addition, recent studies of combination therapies are examined, helping clinicians better understand how to treat the complicated patients that arrive every day at a prescribing clinician's office. Finally, because research designs now include a broader base of patient populations to make the data more applicable to everyday clinical practice, the book focuses on head-to-head studies with multiple active comparators. The book offers clinicians comprehensive, accessible information and boasts a multitude of helpful features: The book is organized by diagnosis instead of agent class. This makes it a true clinical desktop reference that allows clinicians to quickly and efficiently search treatment options and the evidence base on a case-by-case basis. DSM-5 criteria and information on comorbidities are also included. The American Academy of Child and Adolescent Psychiatry Practice Parameters are integrated into the discussion, where applicable, in support of standard of care. The book has been updated to include the latest research at the time of publication. A new chapter has been added to address eating disorders, an area where psychopharmacological research that may apply to children and adolescents is now being pursued. Useful features to help the reader understand and retain the material include clinical summary points, easy to read tables, and current and carefully vetted references. The Clinical Manual of Child and Adolescent Psychopharmacology, Third Edition, is an indispensable guide to the substantive research that has been done in nearly every area of pediatric psychopharmacology, as well as the major improvements that have been made to the evidence-based practice of treating youths with psychiatric illness.